

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/12, C07K 14/705, C12N 15/11, C12Q 1/68, A61K 48/00, C12N 5/10, C07K 16/18, G01N 33/53		A2	(11) International Publication Number: WO 97/00952 (43) International Publication Date: 9 January 1997 (09.01.97)
(21) International Application Number: PCT/US96/10618 (22) International Filing Date: 20 June 1996 (20.06.96) (30) Priority Data: 60/000,352 20 June 1995 (20.06.95) US 08/567,817 6 December 1995 (06.12.95) US (71) Applicant: INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US). (72) Inventors: COLEMAN, Roger; 260 Mariposa #2, Mountain View, CA 94041 (US). GUEGLER, Karl, J.; 1048 Oakland Avenue, Menlo Park, CA 94025 (US). AU-YOUNG, Janice; 1419 Kains Avenue, Berkeley, CA 94702 (US). BANDMAN, Olga; 2309 Rock Street #27, Mountain View, CA 94043 (US). SEILHAMER, Jeffrey, J.; 12555 La Cresta, Los Altos Hills, CA 94022 (US). (74) Agent: GLAISTER, Debra, J.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).		(81) Designated States: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: A HUMAN EDG-2 RECEPTOR HOMOLOG			
(57) Abstract <p>The present invention provides nucleic acid and amino acid sequences that identify and encode a novel EDG-2 receptor homolog (hedg) expressed in human rheumatoid synovium. The present invention also provides for probes for the detection of nucleotide sequences encoding of HEDG or HEDG-like molecules, antisense molecules to the nucleotide sequences which encode HEDG, diagnostic tests based on HEDG encoding nucleic acid molecules, genetically engineered expression vectors and host cells for the production of purified HEDG, antibodies capable of binding specifically to HEDG, and antagonists and inhibitors with specific binding activity for the polypeptide HEDG.</p>			
<p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 1311 1312 1313 1314 1315 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 1329 1330 1331 1332 1333 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390 1391 1392 1393 1394 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 1415 1416 1417 1418 1419 1420 1421 1422 1423 1424 1425 1426 1427 1428 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 1556 1557 1558 1559 1560 1561 1562 1563 1564 1565 1566 1567 1568 1569 1570 1571 1572 1573 1574 1575 1576 1577 1578 1579 1580 1581 1582 1583 1584 1585 1586 1587 1588 1589 1590 1591 1592 1593 1594 1595 1596 1597 1598 1599 1600 1601 1602 1603 1604 1605 1606 1607 1608 1609 1610 1611 1612 1613 1614 1615 1616 1617 1618 1619 1620 1621 1622 1623 1624 1625 1626 1627 1628 1629 1630 1631 1632 1633 1634 1635 1636 1637 1638 1639 1640 1641 1642 1643 1644 1645 1646 1647 1648 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 1662 1663 1664 1665 1666 1667 1668 1669 1670 1671 1672 1673 1674 1675 1676 1677 1678 1679 1680 1681 1682 1683 1684 1685 1686 1687 1688 1689 1690 1691 1692 1693 1694 1695 1696 1697 1698 1699 1700 1701 1702 1703 1704 1705 1706 1707 1708 1709 1710 1711 1712 1713 1714 1715 1716 1717 1718 1719 1720 1721 1722 1723 1724 1725 1726 1727 1728 1729 1730 1731 1732 1733 1734 1735 1736 1737 1738 1739 1740 1741 1742 1743 1744 1745 1746 1747 1748 1749 1750 1751 1752 1753 1754 1755 1756 1757 1758 1759 1760 1761 1762 1763 1764 1765 1766 1767 1768 1769 1770 1771 1772 1773 1774 1775 1776 1777 1778 1779 1780 1781 1782 1783 1784 1785 1786 1787 1788 1789 1790 1791 1792 1793 1794 1795 1796 1797 1798 1799 1800 1801 1802 1803 1804 1805 1806 1807 1808 1809 1810 1811 1812 1813 1814 1815 1816 1817 1818 1819 1820 1821 1822 1823 1824 1825 1826 1827 1828 1829 1830 1831 1832 1833 1834 1835 1836 1837 1838 1839 1840 1841 1842 1843 1844 1845 1846 1847 1848 1849 1850 1851 1852 1853 1854 1855 1856 1857 1858 1859 1860 1861 1862 1863 1864 1865 1866 1867 1868 1869 1870 1871 1872 1873 1874 1875 1876 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 1889 1890 1891 1892 1893 1894 1895 1896 1897 1898 1899 1900 1901 1902 1903 1904 1905 1906 1907 1908 1909 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 1922 1923 1924 1925 1926 1927 1928 1929 1930 1931 1932 1933 1934 1935 1936 1937 1938 1939 1940 1941 1942 1943 1944 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050 2051 2052 2053 2054 2055 2056 2057 2058 2059 2060 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070 2071 2072 2073 2074 2075 2076 2077 2078 2079 2080 2081 2082 2083 2084 2085 2086 2087 2088 2089 2090 2091 2092 2093 2094 2095 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110 2111 2112 2113 2114 2115 2116 2117 2118 2119 2120 2121 2122 2123 2124 2125 2126 2127 2128 2129 2130 2131 2132 2133 2134 2135 2136 2137 2138 2139 2140 2141 2142 2143 2144 2145 2146 2147 2148 2149 2150 2151 2152 2153 2154 2155 2156 2157 2158 2159 2160 2161 2162 2163 2164 2165 2166 2167 2168 2169 2170 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 2184 2185 2186 2187 2188 2189 2190 2191 2192 2193 2194 2195 2196 2197 2198 2199 2200 2201 2202 2203 2204 2205 2206 2207 2208 2209 2210 2211 2212 2213 2214 2215 2216 2217 2218 2219 2220 2221 2222 2223 2224 2225 2226 2227 2228 2229 2230 2231 2232 2233 2234 2235 2236 2237 2238 2239 2240 2241 2242 2243 2244 2245 2246 2247 2248 2249 2250 2251 2252 2253 2254 2255 2256 2257 2258 2259 2260 2261 2262 2263 2264 2265 2266 2267 2268 2269 2270 2271 2272 2273 2274 2275 2276 2277 2278 2279 2280 2281 2282 2283 2284 2285 2286 2287 2288 2289 2290 2291 2292 2293 2294 2295 2296 2297 2298 2299 2300 2301 2302 2303 2304 2305 2306 2307 2308 2309 2310 2311 2312 2313 2314 2315 2316 2317 2318 2319 2320 2321 2322 2323 2324 2325 2326 2327 2328 2329 2330 2331 2332 2333 2334 2335 2336 2337 2338 2339 2340 2341 2342 2343 2344 2345 2346 2347 2348 2349 2350 2351 2352 2353 2354 2355 2356 2357 2358 2359 2360 2361 2362 2363 2364 2365 2366 2367 2368 2369 2370 2371 2372 2373 2374 2375 2376 2377 2378 2379 2380 2381 2382 2383 2384 2385 2386 2387 2388 2389 2390 2391 2392 2393 2394 2395 2396 2397 2398 2399 2400 2401 2402 2403 2404 2405 2406 2407 2408 2409 2410 2411 2412 2413 2414 2415 2416 2417 2418 2419 2420 2421 2422 2423 2424 2425 2426 2427 2428 2429 2430 2431 2432 2433 2434 2435 2436 2437 2438 2439 2440 2441 2442 2443 2444 2445 2446 2447 2448 2449 2450 2451 2452 2453 2454 2455 24</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

A HUMAN EDG-2 RECEPTOR HOMOLOG

TECHNICAL FIELD

5 The present invention is in the field of molecular biology; more particularly, the present invention describes a nucleic acid sequence and an amino acid sequence for a novel human EDG-2 receptor homolog.

BACKGROUND ART

10 The EDG-2 receptor is a putative G-protein coupled seven transmembrane receptor (T7G) which was initially cloned from sheep mRNA (GenBank U18405; Masana MI et al (1994) unpublished). Human edg-1 is commonly grouped with orphan receptors because its endogenous ligand is not known (Hla T and Maciag T (1990) J Biol Chem 265:9308-13). Several T7G receptors have been classified as orphan receptors; they include LCR-1 from brain, the mas oncogene associated with epidermoid carcinoma, RDC-1 known from several major organs, and R334 from rat brain and testis. In some of these cases, a ligand was initially
15 proposed and has since been discounted. The orphan receptors vary in number of amino acids, in molecular weight, in glycosylation sites, and presence and number of disulfide bonds (Watson S and Arkinstall S (1994) The G-Protein Linked Receptor Facts Book, Academic Press, San Diego CA).

20 They are, however, related to other T7Gs by their seven hydrophobic domains which span the plasma membrane and form a bundle of antiparallel α helices. These transmembrane segments (TMS) are designated by roman numerals I-VII and account for structural and functional features of the receptor. In most cases, the bundle of helices forms a binding pocket; however, when the binding site must accommodate more bulky molecules, the extracellular N-terminal segment or one or more of the three extracellular loops participate in binding and in
25 subsequent induction of conformational change in intracellular portions of the receptor. The activated receptor, in turn, interacts with an intracellular G-protein complex which mediates further intracellular signalling activities generally the production of second messengers such as cyclic AMP (cAMP), phospholipase C, inositol triphosphate or ion channel proteins.

30 T7G receptors are expressed and activated during numerous developmental and disease processes. Identification of a novel T7G receptor provides the opportunity to diagnose or intervene in such processes, and the receptor can be used in screening assays to identify physiological or pharmaceutical molecules which trigger, prolong or inhibit its activity.

DISCLOSURE OF THE INVENTION

35 The subject invention provides a unique nucleotide sequence which encodes a novel human EDG-2 receptor homolog (HEDG). The cDNA, herein designated hedg, was identified and cloned using Incyte Clone No. 80853 from a rheumatoid synovium cDNA library.

The invention relates to the use of nucleic acid and amino acid sequences of HEDG, or its variants, in the diagnosis or treatment of activated, inflamed or diseased cells and/or tissues associated with its expression. Aspects of the invention include the antisense DNA of hedg; cloning or expression vectors containing hedg; host cells or organisms transformed with expression vectors containing hedg; a method for the production and recovery of purified HEDG from host cells; and purified protein, HEDG, which can be used to identify inhibitors for the downregulation of signal transduction involving HEDG.

BRIEF DESCRIPTION OF DRAWINGS

Figures 1A and 1B shows the alignment of the nucleic acid sequence (coding region of SEQ ID NO: 1) and amino acid sequence (SEQ ID NO:2) for HEDG. The alignment of the sequences was produced using MacDNAsis software (Hitachi Software Engineering Co Ltd)

Figure 2 displays the alignment of HEDG with sheep EDG-2 (U18405; SEQ ID NO:3) and human EDG-1 (GI 119130; SEQ ID NO:4) receptors. Note the conserved Arg³⁶ and Ser³⁷ cleavage site characteristic of these T7G molecules. Sequences for Fig. 2 were aligned using the multisequence alignment program of DNASTar software (DNASTar Inc, Madison WI).

MODES FOR CARRYING OUT THE INVENTION

As used herein and designated by the upper case abbreviation, HEDG, refers to an EDG2 receptor homolog in either naturally occurring or synthetic form and active fragments thereof which have the amino acid sequence of SEQ ID NO:2. In one embodiment, the polypeptide HEDG is encoded by mRNAs transcribed from the cDNA, as designated by the lower case abbreviation, hedg, of SEQ ID NO:1.

The novel human edg-2 receptor homolog, HEDG, which is the subject of this patent application, was discovered among the partial cDNA sequences (Incyte Clone 80853) expressed in a rheumatoid synovium library. It is more distantly homologous to human edg-1 which was cloned from human vascular endothelial cells and expressed in epithelioid cells, fibroblasts, melanocytes, and vascular smooth muscle cells.

An "oligonucleotide" is a stretch of nucleotide residues which has a sufficient number of bases to be used as an oligomer, primer or probe in a polymerase chain reaction (PCR). Oligonucleotides are prepared from genomic or cDNA sequence and are used to amplify, reveal or confirm the presence of a similar DNA or RNA in a particular cell or tissue. Oligonucleotides or oligomers comprise portions of a DNA sequence having at least about 10 nucleotides and as many as about 35 nucleotides, preferably about 25 nucleotides.

"Probes" may be derived from naturally occurring or recombinant single- or double-stranded nucleic acids or be chemically synthesized. They are useful in detecting the presence of identical or similar sequences.

A "portion" or "fragment" of a polynucleotide or nucleic acid comprises all or any part of the nucleotide sequence having fewer nucleotides than about 6 kb, preferably fewer than about 1 kb which can be used as a probe. Such probes may be labelled with reporter molecules using, nick translation, Klenow fill-in reaction, PCR or other methods well known in the art.
5 After pretesting to optimize reaction conditions and to eliminate false positives, nucleic acid probes may be used in Southern, northern or *in situ* hybridizations to determine whether DNA or RNA encoding HEDG is present in a cell type, tissue, or organ.

"Reporter" molecules are those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents which associate with, establish the presence of, and
10 may allow quantification of a particular nucleotide or amino acid sequence.

"Recombinant nucleotide variants" encoding HEDG may be synthesized by making use of the "redundancy" in the genetic code. Various codon substitutions, such as the silent changes which produce specific restriction sites or codon usage-specific mutations, may be introduced to optimize cloning into a plasmid or viral vector or expression in a particular prokaryotic or
15 eukaryotic host system, respectively.

"Chimeric" molecules may be constructed by introducing all or part of the nucleotide sequence of this invention into a vector containing additional nucleic acid sequence which might be expected to change any one (or more than one) of the following HEDG characteristics: cellular location, distribution, ligand-binding affinities, interchain affinities,
20 degradation/turnover rate, signalling, etc.

"Active" refers to those forms, fragments, or domains of any HEDG polypeptide which retain the biologic and/or antigenic activities of any naturally occurring HEDG.

"Naturally occurring HEDG" refers to a polypeptide produced by cells which have not been genetically engineered and specifically contemplates various polypeptides arising from
25 post-translational modifications of the polypeptide including but not limited to acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation.

"Derivative" refers to those polypeptides which have been chemically modified by such techniques as ubiquitination, labelling (see above), pegylation (derivatization with polyethylene glycol), and chemical insertion or substitution of amino acids such as ornithine
30 which do not normally occur in human proteins.

"Recombinant polypeptide variant" refers to any polypeptide which differs from naturally occurring HEDG by amino acid insertions, deletions and/or substitutions, created using recombinant DNA techniques. Guidance in determining which amino acid residues may be replaced, added or deleted without abolishing activities of interest may be found by comparing
35 the sequence of HEDG with that of related polypeptides and minimizing the number of amino acid

sequence changes made in highly conserved regions.

Amino acid "substitutions" are conservative in nature when they result from replacing one amino acid with another having similar structural and/or chemical properties, such as the replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine.

"Insertions" or "deletions" are typically in the range of about 1 to 5 amino acids. The variation allowed may be experimentally determined by producing the peptide synthetically or by systematically making insertions, deletions, or substitutions of nucleotides in the hedg sequence using recombinant DNA techniques.

A "signal or leader sequence" can be used, when desired, to direct the polypeptide through a membrane of a cell. Such a sequence may be naturally present on the polypeptides of the present invention or provided from heterologous sources by recombinant DNA techniques.

An "oligopeptide" is a short stretch of amino acid residues and may be expressed from an oligonucleotide. It may be functionally equivalent to and the same length as (or considerably shorter than) a "fragment," "portion," or "segment" of a polypeptide. Such sequences comprise a stretch of amino acid residues of at least about 5 amino acids and often about 17 or more amino acids, typically at least about 9 to 13 amino acids, and of sufficient length to display biologic and/or antigenic activity.

"Inhibitor" is any substance which retards or prevents a chemical or physiological reaction or response. Common inhibitors include but are not limited to antisense molecules, antibodies, and antagonists.

"Standard" expression is a quantitative or qualitative measurement for comparison. It is based on a statistically appropriate number of normal samples and is created to use as a basis of comparison when performing diagnostic assays, running clinical trials, or following patient treatment profiles.

"Animal" as used herein may be defined to include human, domestic (cats dogs, etc.), agricultural (cows, horses, sheep, etc) or test species (mouse, rat, rabbit, etc).

The present invention provides a nucleotide sequence uniquely identifying a novel seven transmembrane receptor, human EDG-2 or HEDG. Because HEDG is specifically expressed in inflamed rheumatoid synovium, the nucleic acids (hedg), polypeptides (HEDG) and antibodies to HEDG are useful in diagnostic assays which survey for increased receptor production. Excessive expression of HEDG is likely to be associated with the activation of T lymphocytes and other cells which respond to inflammation and can result in the production of abundant proteases and other molecules which can lead to tissue damage or destruction. Therefore, a diagnostic test for excessive expression of HEDG can accelerate diagnosis and proper treatment

of abnormal conditions caused by viral, bacterial or fungal infections; allergic responses; mechanical injury associated with trauma; hereditary diseases; lymphoma or carcinoma; or other conditions which activate the genes of lymphoid tissues.

The nucleotide sequences encoding HEDG (or their complement) have numerous applications in techniques known to those skilled in the art of molecular biology. These techniques include use as hybridization probes, use in the construction of oligomers for PCR, use for chromosome and gene mapping, use in the recombinant production of HEDG, and use in generation of antisense DNA or RNA, their chemical analogs and the like. Uses of nucleotides encoding HEDG disclosed herein are exemplary of known techniques and are not intended to limit their use in any technique known to a person of ordinary skill in the art. Furthermore, the nucleotide sequences disclosed herein may be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, e.g., the triplet genetic code, specific base pair interactions, etc.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of HEDG-encoding nucleotide sequences may be produced. Some of these will only bear minimal homology to the nucleotide sequence of the known and naturally occurring HEDG. The invention has specifically contemplated each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of naturally occurring hedg, and all such variations are to be considered as being specifically disclosed.

Although the nucleotide sequences which encode HEDG, its derivatives or its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring hedg under stringent conditions, it may be advantageous to produce nucleotide sequences encoding HEDG or its derivatives possessing a substantially different codon usage. Codons can be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic expression host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding HEDG and/or its derivatives without altering the encoded aa sequence include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

Nucleotide sequences encoding HEDG may be joined to a variety of other nucleotide sequences by means of well established recombinant DNA techniques (Sambrook J et al (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor NY; or Ausubel FM et al (1989) Current Protocols in Molecular Biology, John Wiley & Sons,

New York City). Useful nucleotide sequences for joining to hedg include an assortment of cloning vectors such as plasmids, cosmids, lambda phage derivatives, phagemids, and the like. Vectors of interest include expression vectors, replication v ctors, probe generation vectors, sequencing vectors, etc. In general, vectors of interest may contain an origin of replication
5 functional in at least one organism, convenient restriction endonuclease sensitive sites, and selectable markers for one or more host cell systems.

Another aspect of the subject invention is to provide for hedg-specific hybridization probes capable of hybridizing with naturally occurring nucleotide sequences encoding HEDG. Such probes may also be used for the detection of similar T7G encoding sequences and should
10 preferably contain at least 50% of the nucleotides from the hedg sequence. The hybridization probes of the subject invention may be derived from the nucleotide sequence presented as SEQ ID NO:1 or from genomic sequences including promoter, enhancers or introns of the native gene. Hybridization probes may be labeled by a variety of reporter molecules using techniques well known in the art.

15 PCR as described US Patent Nos. 4,683,195; 4,800,195; and 4,965,188 provides additional uses for oligonucleotides based upon the nucleotide sequence which encodes HEDG. Such probes used in PCR may be of recombinant origin, chemically synthesized, or a mixture of both. Oligomers may comprise discrete nucleotide sequences employed under optimized conditions for identification of hedg in specific tissues or diagnostic use. The same two
20 oligomers, a nested set of oligomers, or even a degenerate pool of oligomers may be employed under less stringent conditions for identification of closely related DNAs or RNAs.

Other means of producing specific hybridization probes for hedg include the cloning of nucleic acid sequences encoding HEDG or HEDG derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available and may be used
25 to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerase as T7 or SP6 RNA polymerase and the appropriate reporter molecules.

It is possible to produce a DNA sequence, or portions thereof, entirely by synthetic chemistry. After synthesis, the nucleic acid sequence can be inserted into any of the many available DNA vectors and their respective host cells using techniques which are well known in
30 the art. Moreover, synthetic chemistry may be used to introduce mutations into the nucleotide sequence. Alternately, a portion of sequence in which a mutation is desired can be synthesized and recombined with longer portion of an existing genomic or recombinant sequence.

The nucleotide sequence for hedg can be used in an assay to detect inflammation or disease associated with abnormal levels of HEDG expression. The cDNA can be labeled by methods known
35 in the art, added to a fluid, cell or tissue sample from a patient, and incubated under hybridizing

conditions. After an incubation period, the sample is washed with a compatible fluid which optionally contains a reporter molecule. After the compatible fluid is rinsed off, the reporter molecule is quantitated and compared with a standard as previously defined. If kinase expression is significantly different from standard expression, the assay indicates inflammation or disease.

The nucleotide sequence for *hedg* can be used to construct hybridization probes for mapping the native gene. The gene may be mapped to a particular chromosome or to a specific region of a chromosome using well known mapping techniques. These techniques include *in situ* hybridization of chromosomal spreads (Verma et al (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York City), flow-sorted chromosomal preparations, or artificial chromosome constructions such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions or single chromosome cDNA libraries.

In situ hybridization of chromosomal preparations and physical mapping techniques such as linkage analysis using established chromosomal markers are invaluable in extending genetic maps. Examples of genetic map data can be found in the yearly genome issue of Science (eg 1994, 265:1981f). Often locating a gene on the chromosome of another mammalian species may reveal associated markers which can be used to help identify the analogous human chromosome.

New nucleotide sequences can be assigned to chromosomal subregions by physical mapping. The mapping of new genes or nucleotide sequences provide useful landmarks for investigators searching for disease genes using positional cloning or other gene discovery techniques. Once a disease or syndrome, such as ataxia telangiectasia (AT), has been crudely localized by genetic linkage to a particular genomic region, for example, AT to 11q22-23 (Gatti et al (1988) Nature 336:577-580), any sequences mapping to that area may represent or reveal genes for further investigation. The nucleotide sequence of the subject invention may also be used to detect differences in gene sequence between normal and carrier or affected individuals.

Nucleotide sequences encoding *hedg* may be used to produce a purified oligo- or polypeptide using well known methods of recombinant DNA technology. Goeddel (1990, Gene Expression Technology, Methods and Enzymology, Vol 185, Academic Press, San Diego CA) is one among many publications which teach expression of an isolated nucleotide sequence. The oligopeptide may be expressed in a variety of host cells, either prokaryotic or eukaryotic. Host cells may be from the same species from which the nucleotide sequence was derived or from a different species. Advantages of producing an oligonucleotide by recombinant DNA technology

include obtaining adequate amounts of the protein for purification and the availability of simplified purification procedures.

Cells transformed with DNA encoding HEDG may be cultured under conditions suitable for the expression of T7Gs, their extracellular, transmembrane or intracellular domains and recovery of such peptides from cell culture. HEDG (or any of its domains) produced by a recombinant cell may be secreted or may be contained intracellularly, depending on the particular genetic construction used. In general, it is more convenient to prepare recombinant proteins in secreted form. Purification steps vary with the production process and the particular protein produced. Often an oligopeptide can be produced from a chimeric nucleotide sequence. This is accomplished by ligating the nucleotides from hedg or a desired portion of the polypeptide to a nucleic acid sequence encoding a polypeptide domain which will facilitate protein purification (Kroll DJ et al (1993) DNA Cell Biol 12:441-53).

In addition to recombinant production, fragments of HEDG may be produced by direct peptide synthesis using solid-phase techniques (eg Stewart et al (1969) Solid-Phase Peptide Synthesis, WH Freeman Co, San Francisco CA; Merrifield J (1963) J Am Chem Soc 85:2149-2154. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Foster City, CA) in accordance with the instructions provided by the manufacturer. Additionally, a particular portion of HEDG may be mutated during direct synthesis and combined with other parts of the peptide using chemical methods.

HEDG for antibody induction does not require biological activity; however, the protein must be antigenic. Peptides used to induce specific antibodies may have an aa sequence consisting of at least five aa, preferably at least 10 aa. They should mimic a portion of the aa sequence of the protein and may contain the entire aa sequence of a small naturally occurring molecule such as HEDG. An antigenic portion of HEDG may be fused to another protein such as keyhole limpet hemocyanin, and the chimeric molecule used for antibody production.

Antibodies specific for HEDG may be produced by inoculation of an appropriate animal with the polypeptide or an antigenic fragment. An antibody is specific for HEDG if it is produced against an epitope of the polypeptide and binds to at least part of the natural or recombinant protein. Antibody production includes not only the stimulation of an immune response by injection into animals, but also analogous processes such as the production of synthetic antibodies, the screening of recombinant immunoglobulin libraries for specific-binding molecules (eg Orlandi R et al (1989) PNAS 86:3833-3837, or Huse WD et al (1989) Science 256:1275-1281) or the *in vitro* stimulation of lymphocyte populations. Current technology (Winter G and Milstein C (1991) Nature 349:293-299) provides for a number of highly specific binding reagents based on the principles of antibody formation. These techniques

may be adapted to produce molecules which specifically bind HEDGs.

An additional embodiment of the subject invention is the use of HEDG specific antibodies, inhibitors, receptors or their analogs as bioactive agents to treat inflammation or disease including, but not limited to viral, bacterial or fungal infections; allergic responses; mechanical injury associated with trauma; hereditary diseases; lymphoma or carcinoma; or other conditions which activate the genes of lymphoid tissues.

Bioactive compositions comprising agonists, antagonists, receptors or inhibitors of HEDG may be administered in a suitable therapeutic dose determined by any of several methodologies including clinical studies on mammalian species to determine maximal tolerable dose and on normal human subjects to determine safe dose. Additionally, the bioactive agent may be complexed with a variety of well established compounds or compositions which enhance stability or pharmacological properties such as half-life. It is contemplated that the therapeutic, bioactive composition may be delivered by intravenous infusion into the bloodstream or any other effective means which could be used for treating problems involving excessive lymphocyte and leukocyte trafficking.

Rheumatoid arthritis is currently evaluated on the basis of swelling, response to NSAIDs, x-rays, etc. HEDG is most likely expressed on the surface of the fibroblasts, T and B lymphocytes, monocyte/macrophages, or mast cells which comprise the cells of the inflamed synovium. Once adequate standards are established, an assay for the abnormal expression of HEDG is a viable diagnostic tool for assessing the extent that RA has progressed. The expression of HEDG in a sustained inflammatory response makes it a valuable therapeutic target for screening drug libraries. Inhibitors of HEDG are useful for controlling signal transduction and signaling cascades in cells of the rheumatoid synovium.

The examples below are provided to illustrate the subject invention. These examples are provided by way of illustration and are not included for the purpose of limiting the invention.

INDUSTRIAL APPLICABILITY

I Isolation of mRNA and Construction of the cDNA Library

The hedg sequence of this application was first identified in Incyte Clone No. 80853 among the sequences comprising the rheumatoid synovium library. Rheumatoid synovial tissue was obtained from the hip joint removed from a 68 year old female with erosive, nodular rheumatoid arthritis. The tissue was frozen, ground to powder in a mortar and pestle, and lysed immediately in buffer containing guanidinium isothiocyanate. Lysis was followed by several phenol-chloroform extractions and ethanol precipitations. Poly-A+ mRNA was isolated using biotinylated oligo d(T) and streptavidin coupled to paramagnetic particles (Poly(A) Tract Isolation System, Promega, Madison WI).

Using this Poly-A+ mRNA, a custom cDNA library was constructed by Stratagene (La Jolla CA). Synthesis of cDNA was primed with oligo d(T), and adapter oligonucleotides were ligated onto the cDNA molecules enabling them to be inserted into the Uni-ZAP™ vector system (Stratagene). Alternative unidirectional vectors might include, but are not limited to, pcDNA1 (Invitrogen, San Diego CA) and pSHlox-1 (Novagen, Madison WI).

I I Isolation of cDNA Clones

The phagemid forms of individual cDNA clones were obtained by the in vivo excision process, in which the host bacterial strain was co-infected with both the library phage and an f1 helper phage. Polypeptides or enzymes derived from both the library-containing phage and the helper phage nicked the DNA, initiated new DNA synthesis from defined sequences on the target DNA, and created a smaller, single stranded circular phagemid DNA molecule that included all DNA sequences of the pBluescript phagemid and the cDNA insert. The phagemid DNA was released from the cells, purified, and used to reinfect fresh host cells (SOLR™, Stratagene) where double-stranded DNA was produced.

DNA was purified using the QIAWELL-8 Plasmid Purification System (QIAGEN Inc, Chatsworth CA) an anion-exchange resin system with EMPORE™ membrane technology (3M, Minneapolis MN). The DNA was eluted from the purification resin and prepared for DNA sequencing and other analytical manipulations.

III Sequencing of cDNA Clones

The cDNA inserts from random isolates of the rheumatoid synovium library were sequenced in part. Methods for DNA sequencing are well known in the art. Conventional enzymatic methods employed DNA polymerase Klenow fragment, SEQUENASE® (US Biochemical Corp, Cleveland OH) or Taq polymerase to extend DNA chains from an oligonucleotide primer annealed to the DNA template of interest. Methods have been developed for the use of both single- and double-stranded templates. The chain termination reaction products were electrophoresed on urea-acrylamide gels and detected either by autoradiography (for radionuclide-labeled precursors) or by fluorescence (for fluorescent-labeled precursors). Recent improvements in mechanized reaction preparation, sequencing and analysis using the fluorescent detection method have permitted expansion in the number of sequences that are determined per day using machines such as the Catalyst 800 and the Applied Biosystems 377 or 373 DNA sequencers.

V Homology Searching of cDNA Clones and Deduced Proteins

Each sequence so obtained was compared to sequences in GenBank using a search algorithm developed by Applied Biosystems and incorporated into the INHERIT™ 670 Sequence Analysis System. In this algorithm, Pattern Specification Language (developed by TRW Inc, Los

Angeles CA) was used to determine regions of homology. The three parameters that determine how the sequence comparisons run were window size, window offset, and error tolerance. Using a combination of these three parameters, the DNA database was searched for sequences containing regions of homology to the query sequence, and the appropriate sequences were scored with an initial value. Subsequently, these homologous regions were examined using dot matrix homology plots to distinguish regions of homology from chance matches. Smith-Waterman alignments were used to display the results of the homology search.

Peptide and protein sequence homologies were ascertained using the INHERIT™ 670 Sequence Analysis System in a way similar to that used in DNA sequence homologies. Pattern Specification Language and parameter windows were used to search protein databases for sequences containing regions of homology which were scored with an initial value. Dot-matrix homology plots were examined to distinguish regions of significant homology from chance matches.

Alternatively, BLAST, which stands for Basic Local Alignment Search Tool, is used to search for local sequence alignments (Altschul SF (1993) J Mol Evol 36:290-300; Altschul, SF et al (1990) J Mol Biol 215:403-10). BLAST produces alignments of both nucleotide and aa sequences to determine sequence similarity. Because of the local nature of the alignments, BLAST is especially useful in determining exact matches or in identifying homologs. Whereas it is ideal for matches which do not contain gaps, it is inappropriate for performing motif-style searching. The fundamental unit of BLAST algorithm output is the High-scoring Segment Pair (HSP).

An HSP consists of two sequence fragments of arbitrary but equal lengths whose alignment is locally maximal and for which the alignment score meets or exceeds a threshold or cutoff score set by the user. The BLAST approach is to look for HSPs between a query sequence and a database sequence, to evaluate the statistical significance of any matches found, and to report only those matches which satisfy the user-selected threshold of significance. The parameter E establishes the statistically significant threshold for reporting database sequence matches. E is interpreted as the upper bound of the expected frequency of chance occurrence of an HSP (or set of HSPs) within the context of the entire database search. Any database sequence whose match satisfies E is reported in the program output.

V Identification, Full Length Cloning, Sequencing and Translation

Analysis of INHERIT™ results from randomly picked and sequenced portions of clones from the rheumatoid synovium library identified Incyte 80853 as a homolog of sheep EDG-2 receptor. The partial sequence displayed 92.6% identity with nucleotide sequence of accession U18405 in GenBank (Masana MI et al, supra). The cDNA insert comprising Incyte 80853 was

fully sequenced and used as the basis for cloning the full length cDNA.

The cDNA was extended to full length using a modified XL-PCR (Perkin Elmer) procedure as disclosed in Patent Application Serial No 08/487,112 filed 7 June 1995, and the rheumatoid synovium cDNA library as a template. Primers were designed based on known sequence; one primer was synthesized to initiate extension in the antisense direction (XLR = TCATCTTGATCCCCATCCCTTCTG) and the other to extend sequence in the sense direction (XLF = AGTCTCCGAGTATTGGGTCCTGTG). The primers allowed the sequence to be extended "outward" generating amplicons containing new, unknown nucleotide sequence for the gene of interest. The primers were designed using Oligo 4.0 (National Biosciences Inc, Plymouth MN) to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72° C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations were avoided.

By following the instructions for the XL-PCR kit and thoroughly mixing the enzyme and reaction mix, high fidelity amplification is obtained. Beginning with 25 pMol of each primer and the recommended concentrations of all other components of the kit, PCR was performed using the Peltier Thermal Cycler (PTC200; MJ Research, Watertown MA) and the following parameters:

- Step 1 94° C for 60 sec (initial denaturation)
- Step 2 94° C for 15 sec
- 20 Step 3 65° C for 1 min
- Step 4 68° C for 7 min
- Step 5 Repeat step 2-4 for 15 additional cycles
- Step 6 94° C for 15 sec
- Step 7 65° C for 1 min
- 25 Step 8 68° C for 7 min + 15 sec/cycle
- Step 9 Repeat step 6-8 for 11 additional cycles
- Step 10 72° C for 8 min
- Step 11 4° C (and holding)

At the end of 28 cycles, 50 µl of the reaction mix was removed; and the remaining reaction mix was run for an additional 10 cycles as outlined below:

- Step 1 94° C for 15 sec
- Step 2 65° C for 1 min
- Step 3 68° C for (10 min + 15 sec)/cycle
- Step 4 Repeat step 1-3 for 9 additional cycles
- 35 Step 5 72° C for 10 min

A 5-10 µl aliquot of the reaction mixture was analyzed by electrophoresis on a low concentration (about 0.6-0.8%) agarose mini-gel to determine which reactions were successful in extending the sequence. Although all extensions potentially contain a full length gene, some of the largest products or bands were selected and cut out of the gel. Further purification involved using a commercial gel extraction method such as QIAQuick™ (QIAGEN)

Inc). After recovery of the DNA, Klenow enzyme was used to trim single-stranded, nucleotide overhangs creating blunt ends which facilitated religation and cloning.

After ethanol precipitation, the products were dissolved in 13 μ l of ligation buffer. Then, 1 μ l T4-DNA ligase (15 units) and 1 μ l T4 polynucleotide kinase were added, and the mixture was incubated at room temperature for 2-3 hours or overnight at 16° C. Competent *E. coli* cells (in 40 μ l of appropriate media) were transformed with 3 μ l of ligation mixture and cultured in 80 μ l of SOC medium (Sambrook J et al, supra). After incubation for one hour at 37° C, the whole transformation mixture was plated on Luria Bertani (LB)-agar (Sambrook J et al, supra) containing carbenicillin at 25 mg/L (2xCarb). The following day, 12 colonies were randomly picked from each plate and cultured in 150 μ l of liquid LB/2xCarb medium placed in an individual well of an appropriate, commercially-available, sterile 96-well microtiter plate. The following day, 5 μ l of each overnight culture was transferred into a non-sterile 96-well plate and after dilution 1:10 with water, 5 μ l of each sample was transferred into a PCR array.

For PCR amplification, 15 μ l of concentrated PCR reaction mix (1.33X) containing 0.75 units of Taq polymerase, a vector primer and one or both of the gene specific primers used for the extension reaction were added to each well. Amplification was performed using the following conditions:

Step 1	94° C for 60 sec
Step 2	94° C for 20 sec
Step 3	55° C for 30 sec
Step 4	72° C for 90 sec
Step 5	Repeat steps 2-4 for an additional 29 cycles
Step 6	72° C for 180 sec
Step 7	4° C (and holding)

Aliquots of the PCR reactions were run on agarose gels together with molecular weight markers. The sizes of the PCR products were compared to the original partial cDNAs, and appropriate clones were selected, ligated into plasmid and sequenced.

The nucleotide and aa sequences for human HEDG are shown in Figure 1. The coding region of hedg begins at nucleotide 309 and ends at nucleotide 1403 of SEQ ID NO:1. When the three possible translations of HEDG were searched against protein databases such as SwissProt and PIR, no exact matches were found. Figure 2 shows the comparison between the amino acid sequences of HEDG, sheep EDG-2 (U18405) and human EDG-1 (GI 119130).

VI Antisense analysis

Knowledge of the correct, complete cDNA sequence of HEDG enables its use as a tool for antisense technology in the investigation of gene function. Oligonucleotides, cDNA or genomic fragments comprising the antisense strand of hedg are used either *in vitro* or *in vivo* to inhibit expression of the mRNA. Such technology is now well known in the art, and antisense molecules

can be designed at various locations along the nucleotide sequences. By treatment of cells or whole test animals with such antisense sequences, the gene of interest is effectively turned off. Frequently, the function of the gene is ascertained by observing behavior at the intracellular, cellular, tissue or organismal level (eg, lethality, loss of differentiated function, changes in morphology, etc).

In addition to using sequences constructed to interrupt transcription of a particular open reading frame, modifications of gene expression is obtained by designing antisense sequences to intron regions, promoter/enhancer elements, or even to trans-acting regulatory genes. Similarly, inhibition is achieved using Hogeboom base-pairing methodology, also known as "triple helix" base pairing.

VII Expression of HEDG

Expression of *hedg* is accomplished by subcloning the cDNAs into appropriate expression vectors and transfecting the vectors into analogous expression hosts. In this particular case, the cloning vector previously used for the generation of the cDNA library also provides for direct expression of *hedg* sequences in *E. coli*. Upstream of the cloning site, this vector contains a promoter for β -galactosidase, followed by sequence containing the amino-terminal Met and the subsequent 7 residues of β -galactosidase. Immediately following these eight residues is an engineered bacteriophage promoter useful for artificial priming and transcription and for providing a number of unique endonuclease restriction sites for cloning.

Induction of the isolated, transfected bacterial strain with IPTG using standard methods produces a fusion protein corresponding to the first seven residues of β -galactosidase, about 15 residues of "linker", and the peptide encoded within the cDNA. Since cDNA clone inserts are generated by an essentially random process, there is one chance in three that the included cDNA will lie in the correct frame for proper translation. If the cDNA is not in the proper reading frame, it is obtained by deletion or insertion of the appropriate number of bases using well known methods including *in vitro* mutagenesis, digestion with exonuclease III or mung bean nuclease, or the inclusion of an oligonucleotide linker of appropriate length.

The *hedg* cDNA is shuttled into other vectors known to be useful for expression of protein in specific hosts. Oligonucleotide primers containing cloning sites as well as a segment of DNA (about 25 bases) sufficient to hybridize to stretches at both ends of the target cDNA is synthesized chemically by standard methods. These primers are then used to amplify the desired gene segment by PCR. The resulting gene segment is digested with appropriate restriction enzymes under standard conditions and isolated by gel electrophoresis. Alternately, similar gene segments are produced by digestion of the cDNA with appropriate restriction enzymes. Using appropriate primers, segments of coding sequence from more than one gene are

ligated together and cloned in appropriate vectors. It is possible to optimize expression by construction of such chimeric sequences.

Suitable expression hosts for such chimeric molecules include, but are not limited to, mammalian cells such as Chinese Hamster Ovary (CHO) and human 293 cells, insect cells such as Sf9 cells, yeast cells such as Saccharomyces cerevisiae, and bacteria such as E. coli. For each of these cell systems, a useful expression vector also includes an origin of replication to allow propagation in bacteria and a selectable marker such as the β -lactamase antibiotic resistance gene to allow plasmid selection in bacteria. In addition, the vector may include a second selectable marker such as the neomycin phosphotransferase gene to allow selection in transfected eukaryotic host cells. Vectors for use in eukaryotic expression hosts require RNA processing elements such as 3' polyadenylation sequences if such are not part of the cDNA of interest.

Additionally, the vector contains promoters or enhancers which increase gene expression. Such promoters are host specific and include MMTV, SV40, and metallothionein promoters for CHO cells; trp, lac, tac and T7 promoters for bacterial hosts; and alpha factor, alcohol oxidase and PGH promoters for yeast. Transcription enhancers, such as the rous sarcoma virus enhancer, are used in mammalian host cells. Once homogeneous cultures of recombinant cells are obtained through standard culture methods, large quantities of recombinantly produced HEDG are recovered from the conditioned medium and analyzed using chromatographic methods known in the art.

VIII Isolation of Recombinant HEDG

HEDG is expressed as a chimeric protein with one or more additional polypeptide domains added to facilitate protein purification. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle WA). The inclusion of a cleavable linker sequence such as Factor XA or enterokinase (Invitrogen) between the purification domain and the HEDG sequence is useful to facilitate expression of HEDG.

IX Testing of Chimeric T7Gs

Functional chimeric T7Gs are constructed by combining the extracellular receptive sequences of a new isoform with the transmembrane and intracellular segments of a known isoform for test purposes. This concept was demonstrated by Kobilka et al (1988, Science 240:1310-1316) who created a series of chimeric α 2- β 2 adrenergic receptors (AR) by inserting progressively greater amounts of α 2-AR transmembrane sequence into β 2-AR. The

binding activity of known agonists changed as the molecule shifted from having more $\alpha 2$ than $\beta 2$ conformation, and intermediate constructs demonstrated mixed specificity. The specificity for binding antagonists, however, correlated with the source of the domain VII. The importance of T7G domain VII for ligand recognition was also found in chimeras utilizing two yeast α -factor
5 receptors and is significant because the yeast receptors are classified as miscellaneous receptors. Thus, functional role of specific domains appears to be preserved throughout the T7G family regardless of category.

In parallel fashion, internal segments or cytoplasmic domains from a particular isoform are exchanged with the analogous domains of a known T7G and used to identify the
10 structural determinants responsible for coupling the receptors to trimeric G-proteins (Dohlman et al (1991) *Annu Rev Biochem* 60:653-88). A chimeric receptor in which domains V, VI, and the intracellular connecting loop from $\beta 2$ -AR were substituted into $\alpha 2$ -AR was shown to bind ligands with $\alpha 2$ -AR specificity, but to stimulate adenylate cyclase in the manner of $\beta 2$ -AR. This demonstrates that for adrenergic-type receptors, G-protein
15 recognition is present in domains V and VI and their connecting loop. The opposite situation was predicted and observed for a chimera in which the V->VI loop from $\alpha 1$ -AR replaced the corresponding domain on $\beta 2$ -AR and the resulting receptor bound ligands with $\beta 2$ -AR specificity and activated G-protein-mediated phosphatidylinositol turnover in the $\alpha 1$ -AR manner. Finally, chimeras constructed from muscarinic receptors also demonstrated that V-
20 >VI loop is the major determinant for specificity of G-protein activity (Bolander FF, supra).

Chimeric or modified T7Gs containing substitutions in the extracellular and transmembrane regions have shown that these portions of the receptor determine ligand binding specificity. For example, two Ser residues conserved in domain V of all adrenergic and D catecholamine T7G receptors are necessary for potent agonist activity. These serines are
25 believed to form hydrogen bonds with the catechol moiety of the agonists within the T7G binding site. Similarly, an Asp residue present in domain III of all T7Gs which bind biogenic amines is believed to form an ion pair with the ligand amine group in the T7G binding site.

Functional, cloned T7Gs are expressed in heterologous expression systems and their biological activity assessed (eg Marullo et al (1988) *Proc Natl Acad Sci* 85:7551-55; King et
30 al (1990) *Science* 250:121-23). One heterologous system introduces genes for a mammalian T7G and a mammalian G-protein into yeast cells. The T7G is shown to have appropriate ligand specificity and affinity and trigger appropriate biological activation--growth arrest and morphological changes--of the yeast cells.

An alternate procedure for testing chimeric receptors is based on the procedure
35 utilizing the P_{2U} purinergic receptor (P_{2U}) as published by Erb et al (1993, *Proc Natl Acad*

Sci 90:10449-53). Function is easily tested in cultured K562 human leukemia cells because these cells lack P_{2U} receptors. K562 cells are transfected with expression vectors containing either normal or chimeric P_{2U} and loaded with fura-a, fluorescent probe for Ca^{++} . Activation of properly assembled and functional P_{2U} receptors with extracellular UTP or ATP mobilizes
5 intracellular Ca^{++} which reacts with fura-a and is measured spectrofluorometrically.

As with the T7G receptors above, chimeric genes are created by combining sequences for extracellular receptive segments of any newly discovered T7G polypeptide with the nucleotides for the transmembrane and intracellular segments of the known P_{2U} molecule.

Bathing the transfected K562 cells in microwells containing appropriate ligands triggers
10 binding and fluorescent activity defining effectors of the T7G molecule. Once ligand and function are established, the P_{2U} system is useful for defining antagonists or inhibitors which block binding and prevent such fluorescent reactions.

X Production of HEDG Specific Antibodies

Two approaches are utilized to raise antibodies to HEDG, and each approach is useful for
15 generating either polyclonal or monoclonal antibodies. In one approach, denatured protein from reverse phase HPLC separation is obtained in quantities up to 75 mg. This denatured protein is used to immunize mice or rabbits using standard protocols; about 100 micrograms are adequate for immunization of a mouse, while up to 1 mg might be used to immunize a rabbit. For identifying mouse hybridomas, the denatured protein is radiiodinated and used to screen
20 potential murine B-cell hybridomas for those which produce antibody. This procedure requires only small quantities of protein, such that 20 mg is sufficient for labeling and screening of several thousand clones.

In the second approach, the amino acid sequence of an appropriate HEDG domain, as deduced from translation of the cDNA, is analyzed to determine regions of high antigenicity.
25 Oligopeptides comprising appropriate hydrophilic regions, as illustrated in Figure 3, are synthesized and used in suitable immunization protocols to raise antibodies. Analysis to select appropriate epitopes is described by Ausubel FM et al (supra). The optimal amino acid sequences for immunization are usually at the C-terminus, the N-terminus and those intervening, hydrophilic regions of the polypeptide which are likely to be exposed to the
30 external environment when the protein is in its natural conformation.

Typically, selected peptides, about 15 residues in length, are synthesized using an Applied Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry and coupled to keyhole limpet hemocyanin (KLH; Sigma, St Louis MO) by reaction with M-maleimidobenzoic acid-N-hydroxysuccinimide ester (MBS; Ausubel FM et al, supra). If necessary, a cysteine is

introduced at the N-terminus of the peptide to permit coupling to KLH. Rabbits are immunized with the peptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity by binding the peptide to plastic, blocking with 1% bovine serum albumin, reacting with antisera, washing and reacting with labeled (radioactive or
5 fluorescent), affinity purified, specific goat anti-rabbit IgG.

Hybridomas are prepared and screened using standard techniques. Hybridomas of interest are detected by screening with labeled HEDG to identify those fusions producing the monoclonal antibody with the desired specificity. In a typical protocol, wells of plates (FAST; Becton-Dickinson, Palo Alto CA) are coated during incubation with affinity purified, specific
10 rabbit anti-mouse (or suitable antisppecies Ig) antibodies at 10 mg/ml. The coated wells are blocked with 1% BSA, washed and incubated with supernatants from hybridomas. After washing the wells are incubated with labeled HEDG at 1 mg/ml. Supernatants with specific antibodies bind more labeled HEDG than is detectable in the background. Then clones producing specific antibodies are expanded and subjected to two cycles of cloning at limiting dilution. Cloned
15 hybridomas are injected into pristane-treated mice to produce ascites, and monoclonal antibody is purified from mouse ascitic fluid by affinity chromatography on Protein A. Monoclonal antibodies with affinities of at least 10^8 M⁻¹, preferably 10^9 to 10^{10} or stronger, are typically made by standard procedures as described in Harlow and Lane (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY; and in Goding (1986)
20 Monoclonal Antibodies: Principles and Practice, Academic Press, New York City, both incorporated herein by reference.

XI Diagnostic Test Using HEDG Specific Antibodies

Particular HEDG antibodies are useful for investigating signal transduction and the diagnosis of infectious or hereditary conditions which are characterized by differences in the
25 amount or distribution of HEDG or downstream products of an active signaling cascade. Since HEDG was found in a human rheumatoid library, it appears to be upregulated in cell types mainly involved in immune protection or defense.

Diagnostic tests for HEDG include methods utilizing antibody and a label to detect HEDG in human body fluids, membranes, cells, tissues or extracts of such. The polypeptides and
30 antibodies of the present invention are used with or without modification. Frequently, the polypeptides and antibodies are labeled by joining them, either covalently or noncovalently, with a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known and have been reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors,
35 fluorescent agents, chemiluminescent agents, chromogenic agents, magnetic particles and the

like. Pat nts teaching the use of such labels include US Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. Also, recombinant immunoglobulins may be produced as shown in US Patent No. 4,816,567, incorporated herein by reference.

5 A variety of protocols for measuring soluble or membrane-bound HEDG, using either polyclonal or monoclonal antibodies specific for the protein, are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on HEDG is preferred, but a
10 competitive binding assay may be employed. These assays are described, among other places, in Maddox, DE et al (1983, J Exp Med 158:1211f).

XII Purification of Native HEDG Using Specific Antibodies

Native or recombinant HEDG is purified by immunoaffinity chromatography using antibodies specific for HEDG. In general, an immunoaffinity column is constructed by
15 covalently coupling the anti-TRH antibody to an activated chromatographic resin.

Polyclonal immunoglobulins are prepared from immune sera either by precipitation with ammonium sulfate or by purification on immobilized Protein A (Pharmacia LKB Biotechnology, Piscataway NJ). Likewise, monoclonal antibodies are prepared from mouse ascites fluid by ammonium sulfate precipitation or chromatography on immobilized Protein A.
20 Partially purified immunoglobulin is covalently attached to a chromatographic resin such as CnBr-activated Sepharose (Pharmacia LKB Biotechnology). The antibody is coupled to the resin, the resin is blocked, and the derivative resin is washed according to the manufacturer's instructions.

Such immunoaffinity columns are utilized in the purification of HEDG by preparing a
25 fraction from cells containing HEDG in a soluble form. This preparation is derived by solubilization of whole cells or of a subcellular fraction obtained via differential centrifugation (with or without addition of detergent) or by other methods well known in the art. Alternatively, soluble HEDG containing a signal sequence is secreted in useful quantity into the medium in which the cells are grown.

30 A soluble HEDG-containing preparation is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of HEDG (eg, high ionic strength buffers in the presence of detergent). Then, the column is eluted under conditions that disrupt antibody/protein binding (eg, a buffer of pH 2-3 or a high concentration of a chaotrope such as urea or thiocyanate ion), and HEDG is collected.

XIII Drug Screening

35

This invention is particularly useful for screening therapeutic compounds by using HEDG or binding fragments thereof in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test is either free in solution, affixed to a solid support, borne on a cell surface or located intracellularly. One method of drug screening
5 utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable or fixed form, are used for standard binding assays. One measures, for example, the formation of complexes between HEDG and the agent being tested. Alternatively, one examines the diminution in
10 complex formation between HEDG and a receptor caused by the agent being tested.

Thus, the present invention provides methods of screening for drugs or any other agents which affect signal transduction. These methods, well known in the art, comprise contacting such an agent with HEDG polypeptide or a fragment thereof and assaying (i) for the presence of a complex between the agent and the HEDG polypeptide or fragment, or (ii) for the presence of a
15 complex between the HEDG polypeptide or fragment and the cell. In such competitive binding assays, the HEDG polypeptide or fragment is typically labeled. After suitable incubation, free HEDG polypeptide or fragment is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of the particular agent to bind to HEDG or to interfere with the HEDG and agent complex.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the HEDG polypeptides and is described in detail in European Patent Application 84/03564, published on September 13, 1984, incorporated herein by reference. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test
20 compounds are reacted with HEDG polypeptide and washed. Bound HEDG polypeptide is then detected by methods well known in the art. Purified HEDG are also coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies are used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding HEDG specifically compete with a test compound for
30 binding to HEDG polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic determinants with HEDG.

XIV Rational Drug Design

The goal of rational drug design is to produce structural analogs of biologically active
35 polypeptides of interest or of small molecules with which they interact, agonists, antagonists,

or inhibitors. Any of these examples are used to fashion drugs which are more active or stable forms of the polypeptide or which enhance or interfere with the function of a polypeptide in vivo (eg Hodgson J (1991) Bio/Technology 9:19-21, incorporated herein by reference).

In one approach, the three-dimensional structure of a protein of interest, or of a protein-inhibitor complex, is determined by x-ray crystallography, by computer modeling or, most typically, by a combination of the two approaches. Both the shape and charges of the polypeptide must be ascertained to elucidate the structure and to determine active site(s) of the molecule. Less often, useful information regarding the structure of a polypeptide is gained by modeling based on the structure of homologous proteins. In both cases, relevant structural information is used to design efficient inhibitors. Useful examples of rational drug design includes molecules which have improved activity or stability as shown by Braxton S and Wells JA (1992, Biochemistry 31:7796- 7801) or which act as inhibitors, agonists, or antagonists of native peptides as shown by Athauda SB et al (1993 J Biochem 113:742-46), incorporated herein by reference.

It is also possible to isolate a target-specific antibody, selected by functional assay, as described above, and then to solve its crystal structure. This approach, in principle, yields a pharmacore upon which subsequent drug design is based. It is possible to bypass protein crystallography altogether by generating anti-idiotypic antibodies (anti-ids) to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of the anti-ids is expected to be an analog of the original receptor. The anti-id is then used to identify and isolate peptides from banks of chemically or biologically produced peptides. The isolated peptides then act as the pharmacore.

By virtue of the present invention, sufficient amount of polypeptide are made available to perform such analytical studies as X-ray crystallography. In addition, knowledge of the HEDG amino acid sequence provided herein provides guidance to those employing computer modeling techniques in place of or in addition to x-ray crystallography.

XV Identification of Other Members of the Signal Transduction Complex

The inventive purified HEDG is a research tool for identification, characterization and purification of interacting G or other signal transduction pathway proteins. Radioactive labels are incorporated into a selected HEDG domain by various methods known in the art and used in vitro to capture interacting molecules. A preferred method involves labeling the primary amino groups in HEDG with ¹²⁵I Bolton-Hunter reagent (Bolton, AE and Hunter, WM (1973) Biochem J 133: 529). This reagent has been used to label various molecules without concomitant loss of biological activity (Hebert CA et al (1991) J Biol Chem 266: 18989; McColl S et al (1993) J Immunol 150:4550-4555).

Labeled HEDG is useful as a reagent for the purification of molecules with which it interacts. In one embodiment of affinity purification, membrane-bound HEDG is covalently coupled to a chromatography column. Cell-free extract derived from synovial cells or putative target cells is passed over the column, and molecules with appropriate affinity bind to HEDG. HEDG-complex is recovered from the column, and the HEDG-binding ligand disassociated and subjected to N-terminal protein sequencing. This aa sequence is then used to identify the captured molecule or to design degenerate oligonucleotide probes for cloning the relevant gene from an appropriate cDNA library.

In an alternate method, antibodies are raised against HEDG, specifically monoclonal antibodies. The monoclonal antibodies are screened to identify those which inhibit the binding of labeled HEDG. These monoclonal antibodies are then used therapeutically.

XVI Use and Administration of Antibodies, Inhibitors, or Antagonists

Antibodies, inhibitors, or antagonists of HEDG (or other treatments to limit signal transduction, LST) provide different effects when administered therapeutically. LSTs are formulated in a nontoxic, inert, pharmaceutically acceptable aqueous carrier medium preferably at a pH of about 5 to 8, more preferably 6 to 8, although pH may vary according to the characteristics of the antibody, inhibitor, or antagonist being formulated and the condition to be treated. Characteristics of LSTs include solubility of the molecule, half-life and antigenicity/immunogenicity. These and other characteristics aid in defining an effective carrier. Native human proteins are preferred as LSTs, but organic or synthetic molecules resulting from drug screens are equally effective in particular situations.

LSTs are delivered by known routes of administration including but not limited to topical creams and gels; transmucosal spray and aerosol; transdermal patch and bandage; injectable, intravenous and lavage formulations; and orally administered liquids and pills particularly formulated to resist stomach acid and enzymes. The particular formulation, exact dosage, and route of administration is determined by the attending physician and varies according to each specific situation.

Such determinations are made by considering multiple variables such as the condition to be treated, the LST to be administered, and the pharmacokinetic profile of a particular LST. Additional factors which are taken into account include severity of the disease state, patient's age, weight, gender and diet, time and frequency of LST administration, possible combination with other drugs, reaction sensitivities, and tolerance/response to therapy. Long acting LST formulations might be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular LST.

Normal dosage amounts vary from 0.1 to 100,000 micrograms, up to a total dose of

about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature; see US Patent Nos. 4,657,760; 5,206,344; or 5,225,212. Those skilled in the art employ different formulations for different LSTs. Administration to cells such as nerve cells necessitates delivery in a manner different from that to other cells such as vascular endothelial cells.

It is contemplated that abnormal signal transduction, trauma, or diseases which trigger HEDG activity are treatable with LSTs. These conditions or diseases are specifically diagnosed by the tests discussed above, and such testing should be performed in suspected cases of viral, bacterial or fungal infections; allergic responses; mechanical injury associated with trauma; hereditary diseases; lymphoma or carcinoma; or other conditions which activate the genes of lymphoid tissues.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANT: Coleman, Roger
Guegler, Karl J.
Au-Young, Janice
Bandman, Olga
Seilhamer, Jeffrey J.
- (ii) TITLE OF THE INVENTION: A NOVEL HUMAN EDG-2 RECEPTOR HOMOLOG
- (iii) NUMBER OF SEQUENCES: 6
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Incyte Pharmaceuticals, Inc.
 - (B) STREET: 3174 Porter Drive
 - (C) CITY: Palo Alto
 - (D) STATE: CA
 - (E) COUNTRY: USA
 - (F) ZIP: 94304
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Diskette
 - (B) COMPUTER: IBM Compatible
 - (C) OPERATING SYSTEM: DOS
 - (D) SOFTWARE: FastSEQ Version 1.5
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: TO BE ASSIGNED
 - (B) FILING DATE: 20-JUN-1996
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 60/000,352
 - (B) FILING DATE: 20-JUN-1995
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 08/567,817
 - (B) FILING DATE: 06-DEC-1995
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Glaister, Debra J.
 - (B) REGISTRATION NUMBER: 33,888
 - (C) REFERENCE/DOCKET NUMBER: PF-0042 PCT
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 415-855-0555
 - (B) TELEFAX: 415-845-4166
 - (C) TELEX:

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1875 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vii) IMMEDIATE SOURCE:

(A) LIBRARY: Rheumatoid Synovium

(B) CLONE: 80853

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

GGCAGGTACG GCCGGATTCC CGGGTCGACC ACGCGTCCGC TCTCAAGGGA ACAGCTCCTG      60
CCCAGGTCTG TGGGTACTCA GCATGGATAT CAGTCTCCCT GTGAGTGATG GGAAAGAACT      120
AGCAGAGGTG GACGTCTGAT TTATGAAGCT CCCCATCCAC CTATCTGAGT ACCTGACTTC      180
TCAGGACTGA CACCTACAGC ATCAGGTACA CAGCTTCTCC TAGCATGACT TCGATCTGAT      240
CACCACACAA GAAAATTTGT CTCCCGTAGT TCTGGGGCGT GTTACCACC TACAACCACA      300
GAGCTGTCTAT GGCTGCCATC TCTACTTCCA TCCCTGTAAT TTCACAGCCC CAGTTCACAG      360
CCATGAATGA ACCACAGTGC TTCTACAACG AGTCCATTGC CTTCTTTTAT AACCGAAGTG      420
GAAAGCATCT TGCCACAGAA TGGAACACAG TCAGCAAGCT GGTGATGGGA CTTGGAATCA      480
CTGTTTGTAT CTTTCATCATG TTGGCCAACC TATTGGTCAT GGTGGCAATC TATGTCAACC      540
GCCGCTTCCA TTTTCCATT TATTACCTAA TGGCTAATCT GGCTGCTGCA GACTTCTTTG      600
CTGGGTTGGC CTACTTCTAT CTCATGTTCA ACACAGGACC CAATACTCGG AGACTGACTG      660
TTAGCACATG GCTCCTTCGT CAGGGCCTCA TTGACACCAG CCTGACGGCA TCTGTGGCCA      720
ACTTACTGGC TATTGCAATC GAGAGGCACA TTACGGTTTT CCGCATGCAG CTCCACACAC      780
GGATGAGCAA CCGGCGGGTA GTGGTGGTCA TTGTGGTCAT CTGGACTATG GCCATCGTTA      840
TGGGTGCTAT ACCCAGTGTG GGCTGGAAC TATCTGTGA TATTGAAAAT TGTTCCAACA      900
TGGCACCCCT CTACAGTGAC TCTTACTTAG TCTTCTGGGC CATTTC AAC      960
TTGTGGTAAT GGTGGTTCTC TATGCTCACA TCTTTGGCTA TGTTCCGCCAG AGGACTATGA      1020
GAATGTCTCG GCATAGTTCT GGACCCCGGC GGAATCGGGA TACCATGATG AGTCTTCTGA      1080
AGACTGTGGT CATTGTGCTT GGGGGCTTTA TCATCTGCTG GACTCCTGGA TTGGTTTGT      1140
TACTTCTAGA CGTGTCTGT CCACAGTGCG ACGTGTGGC CTATGAGAAA TTCTTCCTTC      1200
TCCTTGCTGA ATTCAACTCT GCCATGAACC CCATCATTTA CTCCTACCGT GACAAAGAAA      1260
TGAGCGCCAC CTTTAGACAG ATCCTCTGCT GCCAGCGCAG TGAGAACCCC ACCGCCCCCA      1320
CAGAAGGCTC AGACCGCTCG GCTTCTCCC TCAACCACAC CATCTTGGCT GGAGTTCACA      1380
GCAATGACCA CTCTGTGGTT TAGAACGGAA ACTGAGATGA GGAACCAGCC GTCCTCTCTT      1440
GGAGGATAAA CAAGCTCCC CCTACCCAAT TGCCAGGGCA AGGTGGGGTG TGAGAGAGGA      1500
GAAAAGTCAA CTCATGTAAT TAAACACTAA CCAATGACAG TATTTGTTCC TGGACCCAC      1560
AAGACTTGAT ATATATTGAA AATTAGCTTA TGTGACAACC CTCATCTTGA TCCCCATCCC      1620
TTCTGAAAGT AGGAAGTTGG AGCTCTTGCA ATGGAATTCA AGAACAGACT CTGGAGTGTC      1680
CATTTAGACT ACACTAATA GACTTTTAAA AGATTTTGTG TGGTTTGGTG CAAGTCAGAA      1740
TAAATTCTGG CTAGTTGAAT CCACAATTTC ATTTATATAC AGGCTTCCCT TTTTATTTT      1800
TAAAGGATAC GTTTCACCTA ATAAACACGT TTATGCCTAA AAAAAAAAAA AAAAAAAAAA      1860
AAAAAAAAA AAAAC                                     1875

```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 364 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vii) IMMEDIATE SOURCE:

(A) LIBRARY: Rheumatoid Synovium

(B) CLONE: 80853

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

Met Ala Ala Ile Ser Thr Ser Ile Pro Val Ile Ser Gln Pro Gln Phe
 1           5           10           15

```

```

Thr Ala Met Asn Glu Pro Gln Cys Phe Tyr Asn Glu Ser Ile Ala Phe
      20      25      30
Phe Tyr Asn Arg Ser Gly Lys His Leu Ala Thr Glu Trp Asn Thr Val
      35      40      45
Ser Lys Leu Val Met Gly Leu Gly Ile Thr Val Cys Ile Phe Ile Met
      50      55      60
Leu Ala Asn Leu Leu Val Met Val Ala Ile Tyr Val Asn Arg Arg Phe
      65      70      75      80
His Phe Pro Ile Tyr Tyr Leu Met Ala Asn Leu Ala Ala Ala Asp Phe
      85      90      95
Phe Ala Gly Leu Ala Tyr Phe Tyr Leu Met Phe Asn Thr Gly Pro Asn
      100      105      110
Thr Arg Arg Leu Thr Val Ser Thr Trp Leu Leu Arg Gln Gly Leu Ile
      115      120      125
Asp Thr Ser Leu Thr Ala Ser Val Ala Asn Leu Leu Ala Ile Ala Ile
      130      135      140
Glu Arg His Ile Thr Val Phe Arg Met Gln Leu His Thr Arg Met Ser
      145      150      155      160
Asn Arg Arg Val Val Val Val Ile Val Val Ile Trp Thr Met Ala Ile
      165      170      175
Val Met Gly Ala Ile Pro Ser Val Gly Trp Asn Cys Ile Cys Asp Ile
      180      185      190
Glu Asn Cys Ser Asn Met Ala Pro Leu Tyr Ser Asp Ser Tyr Leu Val
      195      200      205
Phe Trp Ala Ile Phe Asn Leu Val Thr Phe Val Val Met Val Val Leu
      210      215      220
Tyr Ala His Ile Phe Gly Tyr Val Arg Gln Arg Thr Met Arg Met Ser
      225      230      235      240
Arg His Ser Ser Gly Pro Arg Arg Asn Arg Asp Thr Met Met Ser Leu
      245      250      255
Leu Lys Thr Val Val Ile Val Leu Gly Gly Phe Ile Ile Cys Trp Thr
      260      265      270
Pro Gly Leu Val Leu Leu Leu Leu Asp Val Cys Cys Pro Gln Cys Asp
      275      280      285
Val Leu Ala Tyr Glu Lys Phe Phe Leu Leu Leu Ala Glu Phe Asn Ser
      290      295      300
Ala Met Asn Pro Ile Ile Tyr Ser Tyr Arg Asp Lys Glu Met Ser Ala
      305      310      315      320
Thr Phe Arg Gln Ile Leu Cys Cys Gln Arg Ser Glu Asn Pro Thr Ala
      325      330      335
Pro Thr Glu Gly Ser Asp Arg Ser Ala Ser Ser Leu Asn His Thr Ile
      340      345      350
Leu Ala Gly Val His Ser Asn Asp His Ser Val Val
      355      360

```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 393 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: GenBank
- (B) CLONE:U18405

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

Met Ala Ala Ala Ser Thr Ser Ser Pro Val Val Ser Gln Pro Gln Phe
1      5      10      15
Thr Ala Met Asn Glu Pro Gln Cys Phe Tyr Asn Glu Ser Ile Ala Phe
20      25      30
Phe Tyr Asn Arg Ser Gly Lys Tyr Leu Ala Thr Glu Trp Asn Thr Val
35      40      45
Ser Lys Leu Val Met Gly Leu Gly Ile Thr Val Cys Ile Phe Ile Met
50      55      60
Leu Ala Asn Leu Leu Val Met Val Ala Ile Tyr Val Asn Arg Arg Phe
65      70      75      80
His Phe Pro Ile Tyr Leu Met Ala Asn Leu Ala Ala Ala Asp Phe
85      90      95
Phe Ala Gly Leu Ala Tyr Phe Tyr Leu Met Phe Asn Thr Gly Pro Asn
100      105      110
Thr Arg Arg Leu Thr Val Ser Thr Trp Leu Leu Arg Gln Gly Leu Ile
115      120      125
Asp Thr Thr Val Thr Ala Ser Val Ala Asn Leu Leu Ala Ile Ala Ile
130      135      140
Glu Arg His Ile Thr Val Phe Arg Met Gln Leu His Thr Arg Met Ser
145      150      155      160
Asn Arg Arg Val Val Val Ile Val Val Ile Trp Thr Met Ala Ile
165      170      175
Val Met Gly Ala Ile Pro Ser Val Gly Trp Asn Cys Ile Cys Asp Ile
180      185      190
Glu Asn Cys Ser Asn Met Ala Pro Leu Tyr Ser Asp Ser Tyr Leu Val
195      200      205
Phe Trp Ala Ile Phe Asn Leu Val Thr Phe Val Val Met Val Val Leu
210      215      220
Tyr Ala His Ile Phe Gly Tyr Val Arg Gln Arg Thr Met Arg Met Ser
225      230      235      240
Arg His Ser Ser Gly Pro Arg Arg Asn Arg Asp Thr Met Met Ser Leu
245      250      255
Leu Lys Thr Val Val Ile Val Leu Gly Ala Phe Ile Ile Cys Trp Thr
260      265      270
Pro Gly Leu Val Leu Leu Leu Leu Asp Val Cys Cys Pro Gln Cys Asp
275      280      285
Val Leu Ala Tyr Glu Lys Phe Phe Leu Leu Leu Ala Glu Phe Asn Ser
290      295      300
Ala Met Asn Pro Ile Ile Tyr Ser Tyr Arg Asp Lys Glu Met Ser Ala
305      310      315      320
Thr Phe Arg Gln Ile Leu Cys Cys Gln Arg Ser Glu Asn Thr Ser Gly
325      330      335
Pro Thr Glu Gly Ser Asp Arg Ser Ala Ser Ser Leu Asn His Thr Ile
340      345      350
Leu Ala Gly Val His Ser Asn Asp His Ser Val Phe Arg Lys Glu Thr
355      360      365
Lys Met Arg Gly Gly His His Leu Leu Arg Asp Glu Gln Pro Pro Pro
370      375      380
Pro Glu Arg Pro Gly Gln Gly Arg Val
385      390

```

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 381 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vii) IMMEDIATE SOURCE:

(A) LIBRARY: GenBank

(B) CLONE: 119130

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met	Gly	Pro	Thr	Ser	Val	Pro	Leu	Val	Lys	Ala	His	Arg	Ser	Ser	Val
1				5					10					15	
Ser	Asp	Tyr	Val	Asn	Tyr	Asp	Ile	Ile	Val	Arg	His	Tyr	Asn	Tyr	Thr
			20				25						30		
Gly	Lys	Leu	Asn	Ile	Ser	Ala	Asp	Lys	Glu	Asn	Ser	Ile	Lys	Leu	Thr
		35					40					45			
Ser	Val	Val	Phe	Ile	Leu	Ile	Cys	Cys	Phe	Ile	Ile	Leu	Glu	Asn	Ile
		50				55					60				
Phe	Val	Leu	Leu	Thr	Ile	Trp	Lys	Thr	Lys	Lys	Phe	His	Arg	Pro	Met
65				70					75					80	
Tyr	Tyr	Phe	Ile	Gly	Asn	Leu	Ala	Leu	Ser	Asp	Leu	Leu	Ala	Gly	Val
			85					90					95		
Ala	Tyr	Thr	Ala	Asn	Leu	Leu	Leu	Ser	Gly	Ala	Thr	Thr	Tyr	Lys	Leu
			100					105					110		
Thr	Pro	Ala	Gln	Trp	Phe	Leu	Arg	Glu	Gly	Ser	Met	Phe	Val	Ala	Leu
		115					120					125			
Ser	Ala	Ser	Val	Phe	Ser	Leu	Leu	Ala	Ile	Ala	Ile	Glu	Arg	Tyr	Ile
	130					135					140				
Thr	Met	Leu	Lys	Met	Lys	Leu	His	Asn	Gly	Ser	Asn	Asn	Phe	Arg	Leu
145				150					155						160
Phe	Leu	Leu	Ile	Ser	Ala	Cys	Trp	Val	Ile	Ser	Leu	Ile	Leu	Gly	Gly
			165						170					175	
Leu	Pro	Ile	Met	Gly	Trp	Asn	Cys	Ile	Ser	Ala	Leu	Ser	Ser	Cys	Ser
		180					185						190		
Thr	Val	Leu	Pro	Leu	Tyr	His	Lys	His	Tyr	Ile	Leu	Phe	Cys	Thr	Thr
	195						200					205			
Val	Phe	Thr	Leu	Leu	Leu	Leu	Ser	Ile	Val	Ile	Leu	Tyr	Cys	Arg	Ile
	210					215					220				
Tyr	Ser	Leu	Val	Arg	Thr	Arg	Ser	Arg	Arg	Leu	Thr	Phe	Arg	Lys	Asn
225				230						235				240	
Ile	Ser	Lys	Ala	Ser	Arg	Ser	Ser	Glu	Asn	Val	Ala	Leu	Leu	Lys	Thr
			245						250					255	
Val	Ile	Ile	Val	Leu	Ser	Val	Phe	Ile	Ala	Cys	Trp	Ala	Pro	Leu	Phe
			260					265					270		
Ile	Leu	Leu	Leu	Asp	Val	Gly	Cys	Lys	Val	Lys	Thr	Cys	Asp	Ile	
	275					280					285				
Leu	Phe	Arg	Ala	Glu	Tyr	Phe	Leu	Val	Leu	Ala	Val	Leu	Asn	Ser	Gly
	290					295					300				
Thr	Asn	Pro	Ile	Ile	Tyr	Thr	Leu	Thr	Asn	Lys	Glu	Met	Arg	Arg	Ala
305				310						315				320	
Phe	Ile	Arg	Ile	Met	Ser	Cys	Cys	Lys	Cys	Pro	Ser	Gly	Asp	Ser	Ala
			325						330				335		
Gly	Lys	Phe	Lys	Arg	Pro	Ile	Ile	Ala	Gly	Met	Glu	Phe	Ser	Arg	Ser
			340					345					350		
Lys	Ser	Asp	Asn	Ser	Ser	His	Pro	Gln	Lys	Asp	Glu	Gly	Asp	Asn	Pro
		355					360					365			
Glu	Thr	Ile	Met	Ser	Ser	Gly	Asn	Val	Asn	Ser	Ser	Ser			
	370					375						380			

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs

(B) TYPE: nucleic acid

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vii) IMMEDIATE SOURCE:
 - (A) Oligomer R

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TCATCTTGAT CCCCATCCCT TCTG

24

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vii) IMMEDIATE SOURCE:
 - (A) Oligomer F

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

AGTCTCCGAG TATTGGGTCC TGTG

24

CLAIMS

1. A purified polynucleotide comprising a nucleic acid sequence encoding the polypeptide of SEQ ID NO:2, or the complement of said polynucleotide.
2. The polynucleotide of Claim 1 comprising the nucleic acid sequence for (hedg) of SEQ ID NO:1.
3. An antisense molecule comprising the complement of the polynucleotide of Claim 2 or a portion thereof.
4. A pharmaceutical composition comprising the antisense molecule of Claim 3 and a pharmaceutically acceptable excipient.
5. A method of treating a subject with a condition associated with altered hedg expression comprising administering an effective amount of the pharmaceutical composition of Claim 4 to the subject.
6. A diagnostic composition comprising an oligomer of the polynucleotide of Claim 2.
7. A diagnostic test for a condition associated with altered hedg expression comprising the steps of:
 - a) providing a biological sample;
 - b) combining the biological sample and the diagnostic composition of Claim 6;
 - c) allowing hybridization to occur between the biological sample and the diagnostic composition under suitable conditions;
 - d) measuring the amount of hybridization to obtain a sample value; and
 - e) comparing the sample value with standard values to determine whether hedg expression is altered.
8. An expression vector comprising the polynucleotide of Claim 1.
9. A host cell transformed with the expression vector of Claim 8.
10. A method for producing a polypeptide, said method comprising the steps of:
 - a) culturing the host cell of Claim 9 under conditions suitable for the expression of the polypeptide; and
 - b) recovering the polypeptide from the host cell culture.
11. A purified polypeptide (HEDG) comprising the amino acid sequence of SEQ ID NO:2.
12. A diagnostic composition comprising the polypeptide of Claim 11 or a portion thereof.
13. A pharmaceutical composition comprising the polypeptide of Claim 11 and a pharmaceutically acceptable excipient.
14. A method of treating a subject with a condition associated with altered HEDG expression comprising administering an effective amount of the pharmaceutical composition of Claim 13 to the subject.

15. An antibody specific for the purified polypeptide of Claim 11, or portion thereof.
16. A diagnostic composition comprising the antibody of Claim 15.
17. A diagnostic test for a condition associated with altered HEDG expression comprising the steps of:
- 5 a) providing a biological sample;
- b) combining the biological sample and the antibody of Claim 15 under conditions suitable for complex formation;
- c) measuring the amount of complex formation between HEDG and the antibody to obtain a sample amount; and
- 10 d) comparing the amount of complex formation in the sample with standard amounts of complex formation, wherein a variation between the sample amount and standard amounts of complex formation establishes the presence of the condition.
18. A method of screening a plurality of compounds for specific binding affinity with the polypeptide of Claim 11 or any portion thereof comprising the steps of:
- 15 a) providing a plurality of compounds;
- b) combining HEDG with each of a plurality of compounds for a time sufficient to allow binding under suitable conditions; and
- c) detecting binding of HEDG to each of the plurality of compounds, thereby identifying the compounds which specifically bind HEDG.
- 20 19. A pharmaceutical composition comprising a compound of Claim 18 and a pharmaceutically acceptable excipient.
20. A method of treating a subject with a condition associated with altered HEDG expression comprising administering an effective amount of the pharmaceutical composition of Claim 19 to the subject.

1/3

```

5'   9      18      27      36      45      54
   ATG GCT GCC ATC TCT ACT TCC ATC CCT GTA ATT TCA CAG CCC CAG TTC ACA GCC
   M  A  A  I  S  T  S  I  P  V  I  S  Q  P  Q  F  T  A

      63      72      81      90      99      108
   ATG AAT GAA CCA CAG TGC TTC TAC AAC GAG TCC ATT GCC TTC TTT TAT AAC CGA
   M  N  E  P  Q  C  F  Y  N  E  S  I  A  F  F  Y  N  R

      117      126      135      144      153      162
   AGT GGA AAG CAT CTT GCC ACA GAA TGG AAC ACA GTC AGC AAG CTG GTG ATG GGA
   S  G  K  H  L  A  T  E  W  N  T  V  S  K  L  V  M  G

      171      180      189      198      207      216
   CTT GGA ATC ACT GTT TGT ATC TTC ATG TTG GCC AAC CTA TTG GTC ATG GTG
   L  G  I  T  V  C  I  F  I  M  L  A  N  L  L  V  M  V

      225      234      243      252      261      270
   GCA ATC TAT GTC AAC CGC CGC TTC CAT TTT CCT ATT TAT TAC CTA ATG GCT AAT
   A  I  Y  V  N  R  R  F  H  F  P  I  Y  Y  L  M  A  N

      279      288      297      306      315      324
   CTG GCT GCT GCA GAC TTC TTT GCT GGG TTG GCC TAC TTC TAT CTC ATG TTC AAC
   L  A  A  A  D  F  F  A  G  L  A  Y  F  Y  L  M  F  N

      333      342      351      360      369      378
   ACA GGA CCC AAT ACT CGG AGA CTG ACT GTT AGC ACA TGG CTC CTT CGT CAG GGC
   T  G  P  N  T  R  R  L  T  V  S  T  W  L  L  R  Q  G

      387      396      405      414      423      432
   CTC ATT GAC ACC AGC CTG ACG GCA TCT GTG GCC AAC TTA CTG GCT ATT GCA ATC
   L  I  D  T  S  L  T  A  S  V  A  N  L  L  A  I  A  I

      441      450      459      468      477      486
   GAG AGG CAC ATT ACG GTT TTC CGC ATG CAG CTC CAC ACA CGG ATG AGC AAC CGG
   E  R  H  I  T  V  F  R  M  Q  L  H  T  R  M  S  N  R

      495      504      513      522      531      540
   CGG GTA GTG GTG GTC ATT GTG GTC ATC TGG ACT ATG GCC ATC GTT ATG GGT GCT
   R  V  V  V  V  I  V  V  I  W  T  M  A  I  V  M  G  A

      549      558      567      576      585      594
   ATA CCC AGT GTG GGC TGG AAC TGT ATC TGT GAT ATT GAA AAT TGT TCC AAC ATG
   I  P  S  V  G  W  N  C  I  C  D  I  E  N  C  S  N  M

      603      612      621      630      639      648
   GCA CCC CTC TAC AGT GAC TCT TAC TTA GTC TTC TGG GCC ATT TTC AAC TTG GTG
   A  P  L  Y  S  D  S  Y  L  V  F  W  A  I  F  N  L  V

      657      666      675      684      693      702
   ACC TTT GTG GTA ATG GTG GTT CTC TAT GCT CAC ATC TTT GGC TAT GTT CGC CAG
   T  F  V  V  M  V  V  L  Y  A  H  I  F  G  Y  V  R  Q

      711      720      729      738      747      756
   AGG ACT ATG AGA ATG TCT CGG CAT AGT TCT GGA CCC CGG CGG AAT CGG GAT ACC
   R  T  M  R  M  S  R  H  S  S  G  P  R  R  N  R  D  T

      765      774      783      792      801      810
   ATG ATG AGT CTT CTG AAG ACT GTG GTC ATT GTG CTT GGG GGC TTT ATC ATC TGC
   M  M  S  L  L  K  T  V  V  I  V  L  G  G  F  I  I  C

      819      828      837      846      855      864
   TGG ACT CCT GGA TTG GTT TTG TTA CTT CTA GAC GTG TGC TGT CCA CAG TGC GAC
   W  T  P  G  L  V  L  L  L  L  D  V  C  C  P  Q  C  D

```

FIGURE 1A

2/3

873 882 891 900 909 918
 GTG CTG GCC TAT GAG AAA TTC TTC CTT CTC CTT GCT GAA TTC AAC TCT GCC ATG
 V L A Y E K F F L L L A E F N S A M

927 936 945 954 963 972
 AAC CCC ATC ATT TAC TCC TAC CGT GAC AAA GAA ATG AGC GCC ACC TTT AGA CAG
 N P I I Y S Y R D K E M S A T F R Q

981 990 999 1008 1017 1026
 ATC CTC TGC TGC CAG CGC AGT GAG AAC CCC ACC GCC CCC ACA GAA GGC TCA GAC
 I L C C Q R S E N P T A P T E G S D

1035 1044 1053 1062 1071 1080
 CGC TCG GCT TCC TCC CTC AAC CAC ACC ATC TTG GCT GGA GTT CAC AGC AAT GAC
 R S A S S L N H T I L A G V H S N D

1089
 CAC TCT GTG GTT TAG 3'
 H S V V *

FIGURE 1B

3/3

1	M A A I S T S I P V I S Q P Q F T A M N E P Q C F Y N E S I	80853
1	M A A A I S T S S P V V S O P O F T A M N E P Q C F Y N E S I	U18405
1	M G P - - T S V P L V K A H R S S V - - - S D Y V N Y D I L	GI 119130
31	A F F Y N R S G K - H L A T E W N T V S K L V M G L G I T V	80853
31	A F F Y N R S G K - Y L A T E W N T V S K L V M G L G I T V	U18405
26	V R H Y N Y T G K L N I S A D K E N S I K L T S V V F I L I	GI 119130
60	C I F I M L A N L L V M V A I Y V N R R F H F P I Y Y L M A	80853
60	C I F I M L A N L L V M V A I Y V N R R F H F P I Y Y L M A	U18405
56	C C F I I L E N I F V L L T I W K T K K F H R P M Y Y F I G	GI 119130
90	N L A A A D F F A G L A Y F Y L M F N T G P N T R R L T V S	80853
90	N L A A A D F F A G L A Y F Y L M F N T G P N T R R L T V S	U18405
86	N L A L S D L L A G V A Y T A N L L L S G A T T Y K L T P A	GI 119130
120	T W L L R Q G L I D T S L T A S V A N L L A I A I E R H I T	80853
120	T W L L R Q G L I D T T V T A S V A N L L A I A I E R H I T	U18405
116	Q W F L R E G S M F V A L S A S V F S L L A I A I E R Y I T	GI 119130
150	V F R M Q L H T R M S N R R V V V V I V V I W T M A I V M G	80853
150	V F R M Q L H T R M S N R R V V V V I V V I W T M A I V M G	U18405
146	M L K M K L H N G S N N F R L F L L I S A C W V I S L I L G	GI 119130
180	A I P S V G W N C I C D I E N C S N M A P L Y S D S Y L V F	80853
180	A I P S V G W N C I C D I E N C S N M A P L Y S D S Y L V F	U18405
176	G L P I M G W N C I S A L S S C S T V L P L Y H K H Y I L F	GI 119130
210	- W A I F N L V T F V V M V V L Y A H I F G Y V R Q R T M R	80853
210	- W A I F N L V T F V V M V V L Y A H I F G Y V R Q R T M R	U18405
206	C T T V F T L L - L L S I V I L Y C R I Y S L V R T R S R R	GI 119130
239	M S R H S S G P R R N R D T M - M S L L K T V V I V L G G F	80853
239	M S R H S S G P R R N R D T M - M S L L K T V V I V L G A F	U18405
235	L T F R K N I S K A S R S S E N V A L L K T V I I V L S V F	GI 119130
268	I I C W T P G L V L L L L D V C C P - - Q C D V L A Y E K F	80853
268	I I C W T P G L V L L L L D V C C P - - Q C D V L A Y E K F	U18405
265	I A C W A P L F I L L L L D V G C K V K T C D I L F R A E Y	GI 119130
296	F L L L A E F N S A M N P I I Y S Y R D K E M S A T F R Q I	80853
296	F L L L A E F N S A M N P I I Y S Y R D K E M S A T F R Q I	U18405
295	F L V L A V L N S G T N P I I Y T L T N K E M R R A F I R I	GI 119130
326	L C C Q R S E N P T A P T E G S D R S A S S L N H T I L A G	80853
326	L C C Q R S E N T S G P T E G S D R S A S S L N H T I L A G	U18405
325	M S C C K C P - - - - - S G D S A G K F K R P I I A G	GI 119130
356	V H S N D H S V -	80853
356	V H S N D H S V F R K E T K M R G G H H L L R D E Q P P P P	U18405
347	M E - - - - - F S R - S K S D N S S H P Q K D E G D N P E	GI 119130
364	- - - - - V	80853
386	E R P G Q G R V	U18405
370	T I M S S G N V N S S S	GI 119130

Decoration 'Decoration #1': Box residues that match 80853 exactly.

FIGURE 2